

Syntheses of (*R*)-(+)-cibenzoline and analogues via catalytic enantioselective cyclopropanation using (*S*)-phenylalanine-derived disulfonamide

Tsuyoshi Miura, Yasuoki Murakami and Nobuyuki Imai*

Faculty of Pharmaceutical Sciences, Chiba Institute of Science, 15-8 Shiomi-cho, Choshi, Chiba 288-0025, Japan

Received 25 October 2006; accepted 15 November 2006

Available online 12 December 2006

Abstract—Cyclopropanation of 3,3-diaryl-2-propen-1-ols **1** with Et₂Zn and CH₂I₂ proceeded in the presence of a catalytic amount of (*S*)-2-(methanesulfonyl)amino-1-(*p*-toluenesulfonyl)amino-3-phenylpropane **2** to afford the corresponding cyclopropylmethanols with 20–76% ee. (+)-2,2-Diphenylcyclopropylmethanol **3a** (76% ee) was oxidized with IBX in DMSO, followed by NaClO₂, H₂O₂, and NaH₂PO₄ in MeCN–H₂O to give the corresponding acid **5a**, which was converted with ethylenediamine, in the presence of PyBOP and Et₃N in CH₂Cl₂, to the amide **6a** in quantitative overall yield from **3a**. Amide **6a** was cyclized at 160 °C under reduced pressure (2 mmHg) to afford (*R*)-(+)-cibenzoline in 55% yield.


© 2006 Elsevier Ltd. All rights reserved.

1. Introduction

Cibenzoline is a commercially available medicine as a class I antiarrhythmic agent¹ and consists of four rings, such as a cyclopropane skeleton which has a stereogenic carbon, two benzene ones, and an imidazoline one. Since Kobayashi reported the first and unique enantioselective Simmons–Smith cyclopropanation catalyzed by a C₂-symmetrical disulfonamide–zinc or aluminum complex,^{2e,h–j} Denmark has optimized conditions for Kobayashi's method.^{2d,f,g} Recently, Charette has developed another enantioselective catalytic cyclopropanation using 25 mol % of C₂-symmetrical titanium complex of (4*R*,5*R*)-2,2-diethyl- α,α',α' -tetraphenyl-1,3-dioxane-4,5-dimethanol (Ti-TADDOLate), which is a large and complex molecule.^{2c} We have developed a catalytic enantioselective Simmons–Smith reaction^{2a,b} and alkylation^{3a} using the simple disulfonamides derived from α -amino acids. Herein, we report a catalytic enantioselective cyclopropanation of 3,3-diaryl-2-propen-1-ols **1**⁴ with Et₂Zn and CH₂I₂ using 10 mol % of (*S*)-2-(methanesulfonyl)amino-1-(*p*-toluenesulfonyl)amino-3-phenylpropane **2** and synthesis of optically active cibenzoline and some analogues.

2. Results and discussion

In a preliminary investigation, the reaction of 3,3-diphenyl-2-propen-1-ol **1a** with Et₂Zn and CH₂I₂ in the presence of 10 mol % of **2** afforded the corresponding cyclopropane product **3a**⁵ with 76% ee, as indicated in entry 1 of Table 1. The cyclopropanation of 3,3-diaryl-2-propen-1-ols substituted on the aromatic ring by electron-donating or electron-withdrawing groups was then examined: the results from the cyclopropanation of various 3,3-diaryl-2-propen-1-ols **1b–1f** with Et₂Zn and CH₂I₂ in the presence of 10 mol % of **2** are collected in Table 1. We selected methoxy and methyl substituents as representative electron-donating groups (see entries 2 and 3), trifluoromethyl and chloro substituents as electron-withdrawing groups (see entries 4 and 5), and a fluorenyl substituent for making the spiro-ring (see entry 6). Fortunately, cyclopropanation of un-substituted allylic alcohol **1a**, which can be converted to cibenzoline gave the highest ee among these 3,3-diaryl-2-propen-1-ols **1a–1f**. The reactions of the allylic alcohols



* Corresponding author. Tel./fax: +81 479 30 4610; e-mail: nimai@cis.ac.jp

Table 1. Cyclopropanation of 3,3-diaryl-2-propen-1-ols **1a–f** in the presence of **2**^a

Entry	1	Ar	Yield (%)	ee ^b (%)	Eluent ^c (%)	$[\alpha]_D^{25}$
1	1a	Ph	82	76	5	+115.9 (<i>c</i> 1.07, CHCl ₃)
2	1b	4-MeOC ₆ H ₄	40	48	5	+60.4 (<i>c</i> 1.41, CHCl ₃)
3	1c	4-MeC ₆ H ₄	71	67	5	+95.4 (<i>c</i> 1.33, CHCl ₃)
4	1d	4-CF ₃ C ₆ H ₄	84	20	5	+13.4 (<i>c</i> 1.29, CHCl ₃)
5	1e	4-ClC ₆ H ₄	32	29	5	+30.6 (<i>c</i> 1.58, CHCl ₃)
6	1f	Fluorenyl	54	51	5	+9.4 (<i>c</i> 1.41, CHCl ₃)

^a All reactions were carried out with 1 equiv of 3,3-diaryl-2-propen-1-ol **1**, 0.1 equiv of **2**, 2 equiv of Et₂Zn, and 3 equiv of CH₂I₂ in anhydrous CH₂Cl₂.

^b Determined by HPLC analysis using Chiralcel OD.

^c The number indicates concentration of *i*-PrOH in hexane as an eluent on HPLC analysis for determination of enantiomeric excess of the product.

1b and **1c** (entries 2 and 3, respectively) substituted with an electron-donating group afforded higher enantioselectivities than those of the allylic alcohols **1d** and **1e** (entries 4 and 5, respectively) substituted with an electron-withdrawing group.

(*R*)-(+)-Cibenzoline was synthesized from (+)-2,2-diphenylcyclopropylmethanol **3a** as follows. Alcohol **3a** was oxidized with 2-iodoxybenzoic acid (IBX) in dimethylsulfoxide (DMSO) at rt for 3 h to afford the corresponding aldehyde **4a**, which was treated with NaClO₂, H₂O₂, and NaH₂PO₄ in MeCN–H₂O at rt for 30 min to give acid **5a**. Acid **5a** was condensed with ethylenediamine in the presence of benzotriazol-1-yloxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) and Et₃N in CH₂Cl₂ at rt for 5 h to obtain the corresponding amide **6a** in quantitative overall yield from **3a**. Then, amide **6a** was con-

verted under reduced pressure (2 mmHg) at 160 °C for 37 h to (*R*)-(+)-cibenzoline⁷ in 55% yield, as shown in Scheme 1. These results suggest that the absolute configurations of compounds **3a–6a** are (*R*). The fluorenyl alcohol **3f**, which is connected at the *ortho*-position of each benzene ring in **3a**, was converted to the corresponding amide **6f** in quantitative overall yield in a similar manner to that described for the preparation of **6a**, Scheme 2. The amide **6f** was not cyclized and recovered in 52% yield under reduced pressure (2 mmHg) at 160 °C for 26 h. It was found that the fluorenyl group of the amide **6f** stereochemically hinders the formation of the imidazoline ring because the two benzene rings of **6f** are fixed in the same plane.

Cyclopropanemethanols **3c**, **3d**, **3e** which are substituted with methyl, trifluoromethyl, chloro groups at the *para*-po-




**Scheme 1.** Synthesis of (*R*)-(+)-cibenzoline from (+)-2,2-diphenylcyclopropylmethanol **3a**.**Scheme 2.** Trial for the preparation of a cibenzoline analogue from (+)-cyclopropylmethanol **3f**.

Table 2. Synthesis of (*R*)-(+)-cibenzoline and the analogues from (+)-2,2-diarylcyclopropylmethanols **3a–3f**

Entry	3	Ar	6		Cibenzoline and the analogues	
			Yield ^a (%)	[α] _D ²⁵	Yield (%)	[α] _D ²⁵
1	3a	Ph	Quant.	+102.8 (<i>c</i> 1.03, MeOH)	55	+30.1 (<i>c</i> 1.12, MeOH)
2	3b	4-MeOC ₆ H ₄	0	—	—	—
3	3c	4-MeC ₆ H ₄	Quant.	+23.9 (<i>c</i> 1.38, MeOH)	43	+25.6 (<i>c</i> 0.64, MeOH)
4	3d	4-CF ₃ C ₆ H ₄	89	+19.2 (<i>c</i> 1.27, MeOH)	46	+21.6 (<i>c</i> 0.75, MeOH)
5	3e	4-ClC ₆ H ₄	55	+38.7 (<i>c</i> 1.39, MeOH)	50	+3.3 (<i>c</i> 0.67, MeOH)
6	3f	Fluorenyl	Quant.	+97.4 (<i>c</i> 1.63, MeOH)	0	—

^a Overall yields from the cyclopropylmethanols **3a–3f**.

sition on the benzene rings were converted to the corresponding cibenzoline analogues in similar methods to the preparation of cibenzoline. All specific rotations of amide **6a–6f**, cibenzoline, and cibenzoline analogues are summarized in Table 2.

3. Conclusion

In summary, (*S*)-2-(methanesulfonyl)amino-1-(*p*-toluenesulfonyl)amino-3-phenylpropane **2** works efficiently as a catalyst in the Simmons–Smith cyclopropanation of sterically hindered allylic alcohols such as 3,3-diaryl-2-propen-1-ols **1a–1f**. In our procedure, it is possible to prepare various chiral 2,2-disubstituted cyclopropylmethanols conveniently and to synthesize the corresponding chiral cibenzoline analogues. We are still working on the optimization of α -amino acid-derived chiral disulfonamides for the catalytic enantioselective cyclopropanation of 3,3-diphenyl-2-propen-1-ol **1a**.

Acknowledgements

This work was supported in part by Ajinomoto Award in Synthetic Organic Chemistry, Japan and by Grants-in-Aid for Scientific Research (C) (No. 18590014) from the Japan Society for the Promotion of Science. This work was performed through the Scientific Research Project by CIS (Chiba Institute of Science).

References

- (a) Martoin, E.; Quinke, K.; Spahn, H.; Mutschler, E. *Chirality* **1989**, *1*, 223–234, and the references cited therein; (b) Tilley, J. W.; Clader, J. W.; Wirkus, M.; Blount, J. F. *J. Org. Chem.* **1985**, *50*, 2220–2224.
- (a) Imai, N.; Nomura, T.; Yamamoto, S.; Ninomiya, Y.; Nokami, J. *Tetrahedron: Asymmetry* **2002**, *13*, 2433–2438; (b) Imai, N.; Sakamoto, K.; Maeda, M.; Kouge, K.; Yoshizane, K.; Nokami, J. *Tetrahedron Lett.* **1997**, *38*, 1423–1426; For the other catalytic enantioselective Simmons–Smith cyclopropanation: (c) Charette, A. B.; Molinaro, C.; Brochu, C. *J. Am. Chem. Soc.* **2001**, *123*, 12168–12175; (d) Denmark, S. E.; O'Connor, S. P. *J. Org. Chem.* **1997**, *62*, 3390–3401; (e) Takahashi, H.; Yoshioka, M.; Shibasaki, M.; Ohno, M.; Imai, N.; Kobayashi, S. *Tetrahedron* **1995**, *51*, 12013–12026; (f) Denmark, S. E.; Christensen, B. L.; Coe, D. M.; O'Connor, S. P. *Tetrahedron Lett.* **1995**, *36*, 2215–2218; (g) Denmark, S. E.; Christensen, B. L.; O'Connor, S. P. *Tetrahedron Lett.* **1995**, *36*, 2219–2222; (h) Imai, N.; Sakamoto, K.; Takahashi, H.; Kobayashi, S. *Tetrahedron Lett.* **1994**, *35*, 7045–7048; (i) Imai, N.; Takahashi, H.; Kobayashi, S. *Chem. Lett.* **1994**, 177–180; (j) Takahashi, H.; Yoshioka, M.; Ohno, M.; Kobayashi, S. *Tetrahedron Lett.* **1992**, *33*, 2575–2578.
- (a) Imai, N.; Nokami, J.; Nomura, T.; Ninomiya, Y.; Sinobe, A.; Matsushiro, S. *The Bull. Okayama Univ. Sci.* **2002**, *38A*, 47–52; For the other catalytic enantioselective alkylation with Et₂Zn in the presence of disulfonamide: (b) Takahashi, H.; Kawakita, T.; Ohno, M.; Yoshioka, M.; Kobayashi, S. *Tetrahedron* **1992**, *48*, 5691–5700; (c) Takahashi, H.; Kawakita, T.; Yoshioka, M.; Ohno, M. *Tetrahedron Lett.* **1989**, *30*, 7095–7098; (d) Yoshioka, M.; Kawakita, T.; Ohno, M. *Tetrahedron Lett.* **1989**, *30*, 1657–1660.
- Imai, N.; Noguchi, T.; Nokami, J.; Otera, J. *The Bull. Okayama Univ. Sci.* **2003**, *39A*, 47–55.
- (a) Turnbull, M. D. *J. Chem. Soc., Perkin Trans. 1* **1997**, 1241–1247; (b) Watanabe, N.; Matsuda, H.; Kuribayashi, H.; Hashimoto, S. *Heterocycles* **1996**, *42*, 537–542, and the references cited therein.
- Compound **6a**: ¹H NMR (CD₃OD) δ 1.50 (1H, dd, *J* = 5.0, 8.2 Hz), 2.16 (1H, dd, *J* = 5.0, 5.9 Hz), 2.53 (1H, dd, *J* = 5.9, 8.2 Hz), 2.73 (2H, m), 3.23 (2H, t, *J* = 6.2 Hz), 7.12–7.36 (10H, m); ¹³C NMR (CD₃OD) δ 19.4, 31.0, 38.6, 40.2, 41.1, 127.5, 127.9, 128.7, 129.3, 129.4, 130.9, 142.0, 146.6, 173.6; HRMS (ESI-TOF): Calcd for C₁₈H₂₁N₂O (M+H⁺): 281.1648. Found: 281.1654.
- (*R*)-(+)-Cibenzoline: ¹H NMR (CD₃OD) δ 1.58 (1H, dd, *J* = 5.4, 8.6 Hz), 2.09 (1H, dd, *J* = 5.4, 6.3 Hz), 2.43 (1H, dd, *J* = 6.3, 8.6 Hz), 3.20 (2H, m), 3.37 (2H, m), 7.11–7.38 (10H, m); ¹³C NMR (CD₃OD) δ 19.5, 25.2, 30.8, 39.9, 48.9, 127.6, 128.1, 128.8, 129.3, 129.5, 131.0, 141.4, 146.4, 168.9; HRMS (ESI-TOF): Calcd for C₁₈H₁₉N₂ (M+H⁺): 263.1543. Found: 263.1540.